加压素和加压素V1a型受体激动剂加压素在感染性休克中的作用
The Role of Vasopressin and the Vasopressin Type V1a Receptor Agonist Selepressin in Septic Shock
DOI: 10.12677/acm.2025.1551359, PDF,    科研立项经费支持
作者: 刘 澳：内蒙古医科大学包头临床医学院，内蒙古 包头；王君艳*：包头市中心医院重症医学科，内蒙古 包头
关键词: 加压素；休克；感染性休克；Vasopressin； Shock； Septic Shock
摘要: 感染性休克仍然是危重病人发病和死亡的主要原因之一。尽管进行了早期目标治疗并给予了链胆胺能药物，但仍有高达30%的患者死于该疾病。在这份手稿中，我们首先总结了感染性休克患者的护理标准和当前的指南。我们回顾了加压素的生理作用及其在脓毒性休克管理中的作用。然后，我们回顾了关于V1a受体激动剂(如加压素)在感染性休克中潜在作用的最新证据。令人兴奋的新试验正在完成，以阐明V1a受体激动剂作为潜在的一线血管加压药替代品在脓毒症患者循环休克治疗中的作用。
Abstract: Septic shock remains one of the major causes of morbidity and mortality in the critically ill. Despite early goal therapy and administration of cathecholaminergic agents, up to 30% of patients succumb to the disease. In this manuscript, we first summarize the standard of care of patients with septic shock and current guidelines. We review the physiologic role of vasopressin and its role in septic shock management. We then review the most up-to-date evidence on the potential role of V1a receptor agonists such as Selepressin, in septic shock. Exciting new trials are being completed in order to elucidate the role of V1a receptor agonists as potential first-line vasopressor alternatives in the therapy of circulatory shock in septic patients.
文章引用：刘澳, 王君艳. 加压素和加压素V1a型受体激动剂加压素在感染性休克中的作用[J]. 临床医学进展, 2025, 15(5): 195-203. https://doi.org/10.12677/acm.2025.1551359

参考文献

[1] Angus, D.C., Linde-Zwirble, W.T., Lidicker, J., Clermont, G., Carcillo, J. and Pinsky, M.R. (2001) Epidemiology of Severe Sepsis in the United States: Analysis of Incidence, Outcome, and Associated Costs of Care. Critical Care Medicine, 29, 1303-1310. [Google Scholar] [CrossRef] [PubMed]
[2] Angus, D., Pires Pereira, C. and Silva, E. (2006) Epidemiology of Severe Sepsis around the World. Endocrine, Metabolic & Immune Disorders-Drug Targets, 6, 207-212. [Google Scholar] [CrossRef] [PubMed]
[3] Kumar, G., Kumar, N., Taneja, A., Kaleekal, T., Tarima, S., McGinley, E., et al. (2011) Nationwide Trends of Severe Sepsis in the 21st Century (2000-2007). Chest, 140, 1223-1231. [Google Scholar] [CrossRef] [PubMed]
[4] Rivers, E., Nguyen, B., Havstad, S., Ressler, J., Muzzin, A., Knoblich, B., et al. (2001) Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock. New England Journal of Medicine, 345, 1368-1377. [Google Scholar] [CrossRef] [PubMed]
[5] Yende, S. and Angus, D.C. (2007) Long-Term Outcomes from Sepsis. Current Infectious Disease Reports, 9, 382-386. [Google Scholar] [CrossRef] [PubMed]
[6] Bone, R.C., Balk, R.A., Cerra, F.B., Dellinger, R.P., Fein, A.M., Knaus, W.A., et al. (1992) Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis. Chest, 101, 1644-1655. [Google Scholar] [CrossRef] [PubMed]
[7] Rhodes, A., Evans, L.E., Alhazzani, W., Levy, M.M., Antonelli, M., Ferrer, R., et al. (2021) Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock. Intensive Care Medicine, 47, 1181-1247.
[8] Russell, J.A., Walley, K.R., Singer, J., Gordon, A.C., Hébert, P.C., Cooper, D.J., et al. (2008) Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock. New England Journal of Medicine, 358, 877-887. [Google Scholar] [CrossRef] [PubMed]
[9] Maybauer, M.O. and Walley, K.R. (2010) Best Vasopressor for Advanced Vasodilatory Shock: Should Vasopressin Be Part of the Mix? Intensive Care Medicine, 36, 1484-1487. [Google Scholar] [CrossRef] [PubMed]
[10] Maybauer, M.O. and Maybauer, D.M. (2011) Vasopressin Analogues and V1a Receptor Agonists in Septic Shock. Inflammation Research, 60, 425-427. [Google Scholar] [CrossRef] [PubMed]
[11] Chopra, M. and Sharma, A.C. (2009) Contractile Response of Norepinephrine Is Modulated by Caspase-3 in Adult Rat Ventricular Myocytes Isolated from Septic Rat Heart. Pharmacological Research, 60, 303-313. [Google Scholar] [CrossRef] [PubMed]
[12] Muthu, K., Deng, J., Gamelli, R., Shankar, R. and Jones, S.B. (2005) Adrenergic Modulation of Cytokine Release in Bone Marrow Progenitor-Derived Macrophage Following Polymicrobial Sepsis. Journal of Neuroimmunology, 158, 50-57. [Google Scholar] [CrossRef] [PubMed]
[13] Ensinger, H., Weichel, T., Lindner, K., Grünert, A. and Georgieff, M. (1995) Are the Effects of Noradrenaline, Adrenaline and Dopamine Infusions on VO2 and Metabolism Transient? And Metabolism Transient? Intensive Care Medicine, 21, 50-56. [Google Scholar] [CrossRef] [PubMed]
[14] Barth, E., Albuszies, G., Baumgart, K., Matejovic, M., Wachter, U., Vogt, J., et al. (2007) Glucose Metabolism and Catecholamines. Critical Care Medicine, 35, S508-S518. [Google Scholar] [CrossRef] [PubMed]
[15] Annane, D., Vignon, P., Renault, A., Bollaert, P., Charpentier, C., Martin, C., et al. (2007) Norepinephrine Plus Dobutamine versus Epinephrine Alone for Management of Septic Shock: A Randomised Trial. The Lancet, 370, 676-684. [Google Scholar] [CrossRef] [PubMed]
[16] Myburgh, J.A., Higgins, A., Jovanovska, A., Lipman, J., Ramakrishnan, N. and Santamaria, J. (2008) A Comparison of Epinephrine and Norepinephrine in Critically Ill Patients. Intensive Care Medicine, 34, 2226-2234. [Google Scholar] [CrossRef] [PubMed]
[17] De Backer, D., Biston, P., Devriendt, J., Madl, C., Chochrad, D., Aldecoa, C., et al. (2010) Comparison of Dopamine and Norepinephrine in the Treatment of Shock. New England Journal of Medicine, 362, 779-789. [Google Scholar] [CrossRef] [PubMed]
[18] Maybauer, M.O. and Maybauer, D.M. (2015) A New Frontier for an Old Drug? A Word of Caution for Beta-Blockers in Sepsis! Current Medical Research and Opinion, 31, 1829-1830. [Google Scholar] [CrossRef] [PubMed]
[19] Morelli, A., Ertmer, C., Westphal, M., Rehberg, S., Kampmeier, T., Ligges, S., et al. (2013) Effect of Heart Rate Control with Esmolol on Hemodynamic and Clinical Outcomes in Patients with Septic Shock: A Randomized Clinical Trial. JAMA, 310, 1683-1691. [Google Scholar] [CrossRef] [PubMed]
[20] Morelli, A., Singer, M., Ranieri, V.M., D’Egidio, A., Mascia, L., Orecchioni, A., et al. (2016) Heart Rate Reduction with Esmolol Is Associated with Improved Arterial Elastance in Patients with Septic Shock: A Prospective Observational Study. Intensive Care Medicine, 42, 1528-1534. [Google Scholar] [CrossRef] [PubMed]
[21] Huang, S.J., Nalos, M. and McLean, A.S. (2013) Is Early Ventricular Dysfunction or Dilatation Associated with Lower Mortality Rate in Adult Severe Sepsis and Septic Shock? A Meta-Analysis. Critical Care, 17, Article No. R96. [Google Scholar] [CrossRef] [PubMed]
[22] Sanfilippo, F., Corredor, C., Fletcher, N., Landesberg, G., Benedetto, U., Foex, P., et al. (2015) Diastolic Dysfunction and Mortality in Septic Patients: A Systematic Review and Meta-analysis. Intensive Care Medicine, 41, 1004-1013. [Google Scholar] [CrossRef] [PubMed]
[23] Schrier, R.W., Berl, T. and Anderson, R.J. (1979) Osmotic and Nonosmotic Control of Vasopressin Release. American Journal of Physiology-Renal Physiology, 236, F321-F332. [Google Scholar] [CrossRef] [PubMed]
[24] Maybauer, M.O., Maybauer, D.M., Enkhbaatar, P. and Traber, D.L. (2008) Physiology of the Vasopressin Receptors. Best Practice & Research Clinical Anaesthesiology, 22, 253-263. [Google Scholar] [CrossRef] [PubMed]
[25] Howl, J. and Wheatley, M. (1995) Molecular Pharmacology of V1a Vasopressin Receptors. General Pharmacology: The Vascular System, 26, 1143-1152. [Google Scholar] [CrossRef] [PubMed]
[26] Oshikawa, S., Tanoue, A., Koshimizu, T., Kitagawa, Y. and Tsujimoto, G. (2004) Vasopressin Stimulates Insulin Release from Islet Cells through V1b Receptors: A Combined Pharmacological/Knockout Approach. Molecular Pharmacology, 65, 623-629. [Google Scholar] [CrossRef] [PubMed]
[27] Barberis, C., Mouillac, B. and Durroux, T. (1998) Structural Bases of Vasopressin/Oxytocin Receptor Function. Journal of Endocrinology, 156, 223-229. [Google Scholar] [CrossRef] [PubMed]
[28] Jard, S. (1998) Vasopressin Receptors. In: Zingg, H.H., Bourque, C.W. and Bichet, D.G., Eds., Vasopressin and Oxytocin, Springer, 1-13. [Google Scholar] [CrossRef] 
[29] Ring, R. (2005) The Central Vasopressinergic System: Examining the Opportunities for Psychiatric Drug Development. Current Pharmaceutical Design, 11, 205-225. [Google Scholar] [CrossRef] [PubMed]
[30] Evora, P.R.B., Pearson, P.J., Rodrigues, A.J., Viaro, F. and Schaff, H.V. (2003) Effect of Arginine Vasopressin on the Canine Epicardial Coronary Artery: Experiments on V1-Receptor-Mediated Production of Nitric Oxide. Arquivos Brasileiros de Cardiologia, 80, 489-494. [Google Scholar] [CrossRef] [PubMed]
[31] Sai, Y., Okamura, T., Amakata, Y. and Toda, N. (1995) Comparison of Responses of Canine Pulmonary Artery and Vein to Angiotensin II, Bradykinin and Vasopressin. European Journal of Pharmacology, 282, 235-241. [Google Scholar] [CrossRef] [PubMed]
[32] Antoni, F.A., Holmes, M.C., Makara, G.B., Kárteszi, M. and László, F.A. (1984) Evidence That the Effects of Arginine-8-Vasopressin (AVP) on Pituitary Corticotropin (ACTH) Release Are Mediated by a Novel Type of Receptor. Peptides, 5, 519-522. [Google Scholar] [CrossRef] [PubMed]
[33] Hernando, F., Schoots, O., Lolait, S.J. and Burbach, J.P.H. (2001) Immunohistochemical Localization of the Vasopressin V1b Receptor in the Rat Brain and Pituitary Gland: Anatomical Support for Its Involvement in the Central Effects of Vasopressin. Endocrinology, 142, 1659-1668. [Google Scholar] [CrossRef] [PubMed]
[34] Holmes, C.L., Landry, D.W. and Granton, J.T. (2003) Science Review: Vasopressin and the Cardiovascular System Part 1-Receptor Physiology. Critical Care, 7, 427-434. [Google Scholar] [CrossRef] [PubMed]
[35] Knepper, M.A. and Inoue, T. (1997) Regulation of Aquaporin-2 Water Channel Trafficking by Vasopressin. Current Opinion in Cell Biology, 9, 560-564. [Google Scholar] [CrossRef] [PubMed]
[36] O’Connor, P.M. and Cowley, A.W. (2007) Vasopressin-induced Nitric Oxide Production in Rat Inner Medullary Collecting Duct Is Dependent on V2 Receptor Activation of the Phosphoinositide Pathway. American Journal of Physiology-Renal Physiology, 293, F526-F532. [Google Scholar] [CrossRef] [PubMed]
[37] Park, F., Zou, A. and Cowley, A.W. (1998) Arginine Vasopressin-Mediated Stimulation of Nitric Oxide within the Rat Renal Medulla. Hypertension, 32, 896-901. [Google Scholar] [CrossRef] [PubMed]
[38] Kaufmann, J.E., Oksche, A., Wollheim, C.B., Günther, G., Rosenthal, W. and Vischer, U.M. (2000) Vasopressin-Induced Von Willebrand Factor Secretion from Endothelial Cells Involves V2 Receptors and cAMP. Journal of Clinical Investigation, 106, 107-116. [Google Scholar] [CrossRef] [PubMed]
[39] Thibonnier, M., Conarty, D.M., Preston, J.A., Plesnicher, C.L., Dweik, R.A. and Erzurum, S.C. (1999) Human Vascular Endothelial Cells Express Oxytocin Receptors. Endocrinology, 140, 1301-1309. [Google Scholar] [CrossRef] [PubMed]
[40] Gutkowska, J., Jankowski, M., Mukaddam-Daher, S. and McCann, S.M. (2000) Oxytocin Is a Cardiovascular Hormone. Brazilian Journal of Medical and Biological Research, 33, 625-633. [Google Scholar] [CrossRef] [PubMed]
[41] Indrambarya, T., Boyd, J.H., Wang, Y., McConechy, M. and Walley, K.R. (2009) Low-Dose Vasopressin Infusion Results in Increased Mortality and Cardiac Dysfunction Following Ischemia-Reperfusion Injury in Mice. Critical Care, 13, Article No. R98. [Google Scholar] [CrossRef] [PubMed]
[42] Mori, M., Tsushima, H. and Matsuda, T. (1994) Antidiuretic Effects of ATP Induced by Microinjection into the Hypothalamic Supraoptic Nucleus in Water-Loaded and Ethanol-Anesthetized Rats. Japanese Journal of Pharmacology, 66, 445-450. [Google Scholar] [CrossRef] [PubMed]
[43] Guo, W., Sun, J., Xu, X., Bunstock, G., He, C. and Xiang, Z. (2008) P2X Receptors Are Differentially Expressed on Vasopressin-And Oxytocin-Containing Neurons in the Supraoptic and Paraventricular Nuclei of Rat Hypothalamus. Histochemistry and Cell Biology, 131, 29-41. [Google Scholar] [CrossRef] [PubMed]
[44] Kaufmann, J.E. and Vischer, U.M. (2003) Cellular Mechanisms of the Hemostatic Effects of Desmopressin (DDAVP). Journal of Thrombosis and Haemostasis, 1, 682-689. [Google Scholar] [CrossRef] [PubMed]
[45] Knepper, M.A. (1997) Molecular Physiology of Urinary Concentrating Mechanism: Regulation of Aquaporin Water Channels by Vasopressin. American Journal of Physiology-Renal Physiology, 272, F3-F12. [Google Scholar] [CrossRef] [PubMed]
[46] Caldwell, H.K. and Albers, H.E. (2015) Oxytocin, Vasopressin, and the Motivational Forces That Drive Social Behaviors. In: Simpson, E. and Balsam, P., Eds., Behavioral Neuroscience of Motivation, Springer, 51-103. [Google Scholar] [CrossRef] [PubMed]
[47] Landry, D.W., Levin, H.R., Gallant, E.M., Ashton, R.C., Seo, S., D’Alessandro, D., et al. (1997) Vasopressin Deficiency Contributes to the Vasodilation of Septic Shock. Circulation, 95, 1122-1125. [Google Scholar] [CrossRef] [PubMed]
[48] Sharshar, T., Blanchard, A., Paillard, M., Raphael, J.C., Gajdos, P. and Annane, D. (2003) Circulating Vasopressin Levels in Septic Shock. Critical Care Medicine, 31, 1752-1758. [Google Scholar] [CrossRef] [PubMed]
[49] Jochberger, S., Dörler, J., Luckner, G., Mayr, V.D., Wenzel, V., Ulmer, H., et al. (2009) The Vasopressin and Copeptin Response to Infection, Severe Sepsis, and Septic Shock. Critical Care Medicine, 37, 476-482. [Google Scholar] [CrossRef] [PubMed]
[50] Sharshar, T., Carlier, R., Blanchard, A., Feydy, A., Gray, F., Paillard, M., et al. (2002) Depletion of Neurohypophyseal Content of Vasopressin in Septic Shock. Critical Care Medicine, 30, 497-500. [Google Scholar] [CrossRef] [PubMed]
[51] Oliver, J.A. and Landry, D.W. (2007) Endogenous and Exogenous Vasopressin in Shock. Current Opinion in Critical Care, 13, 376-382. [Google Scholar] [CrossRef] [PubMed]
[52] Farand, P., Hamel, M., Lauzier, F., Plante, G.E. and Lesur, O. (2006) Review Article: Organ per Fusion/Permeabilityrelated Effects of Norepinephrine and Vasopressin in Sepsis. Canadian Journal of Anesthesia/Journal Canadien D’anesthésie, 53, 934-946. [Google Scholar] [CrossRef] [PubMed]
[53] Barrett, L.K., Singer, M. and Clapp, L.H. (2007) Vasopressin: Mechanisms of Action on the Vasculature in Health and in Septic Shock. Critical Care Medicine, 35, 33-40. [Google Scholar] [CrossRef] [PubMed]
[54] Russell, J.A. (2007) Vasopressin in Septic Shock. Critical Care Medicine, 35, S609-S615. [Google Scholar] [CrossRef] [PubMed]
[55] Russell, J.A. (2007) Vasopressin in Vasodilatory and Septic Shock. Current Opinion in Critical Care, 13, 383-391. [Google Scholar] [CrossRef] [PubMed]
[56] Gordon, A.C., Russell, J.A., Walley, K.R., Singer, J., Ayers, D., Storms, M.M., et al. (2009) The Effects of Vasopressin on Acute Kidney Injury in Septic Shock. Intensive Care Medicine, 36, 83-91. [Google Scholar] [CrossRef] [PubMed]
[57] Russell, J.A., Walley, K.R., Gordon, A.C., Cooper, D.J., Hébert, P.C., Singer, J., et al. (2009) Interaction of Vasopressin Infusion, Corticosteroid Treatment, and Mortality of Septic Shock. Critical Care Medicine, 37, 811-818. [Google Scholar] [CrossRef] [PubMed]
[58] Ertmer, C., Bone, H., Morelli, A., Van Aken, H., Erren, M., Lange, M., et al. (2007) Methylprednisolone Reverses Vasopressin Hyporesponsiveness in Ovine Endotoxemia. Shock, 27, 281-288. [Google Scholar] [CrossRef] [PubMed]
[59] Annane, D. (2009) Vasopressin Plus Corticosteroids: The Shock Duo! Critical Care Medicine, 37, 1126-1127. [Google Scholar] [CrossRef] [PubMed]
[60] Gordon, A.C., Mason, A.J., Thirunavukkarasu, N., Perkins, G.D., Cecconi, M., Cepkova, M., et al. (2016) Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients with Septic Shock: The Vanish Randomized Clinical Trial. JAMA, 316, 509-518. [Google Scholar] [CrossRef] [PubMed]
[61] Oberti, F., Veal, N., Kaassis, M., Pilette, C., Rifflet, H., Trouvé, R., et al. (1998) Hemodynamic Effects of Terlipressin and Octreotide Administration Alone or in Combination in Portal Hypertensive Rats. Journal of Hepatology, 29, 103-111. [Google Scholar] [CrossRef] [PubMed]
[62] Bernadich, C., Bandi, J., Melin, P. and Bosch, J. (1998) Effects of F-180, a New Selective Vasoconstrictor Peptide, Compared with Terlipressin and Vasopressin on Systemic and Splanchnic Hemodynamics in a Rat Model of Portal Hypertension. Hepatology, 27, 351-356. [Google Scholar] [CrossRef] [PubMed]
[63] Asfar, P., Hauser, B., Iványi, Z., Ehrmann, U., Kick, J., Albicini, M., et al. (2005) Low-Dose Terlipressin during Long-Term Hyperdynamic Porcine Endotoxemia: Effects on Hepatosplanchnic Perfusion, Oxygen Exchange, and Metabolism. Critical Care Medicine, 33, 373-380. [Google Scholar] [CrossRef] [PubMed]
[64] Morelli, A., Ertmer, C., Rehberg, S., Lange, M., Orecchioni, A., Cecchini, V., et al. (2009) Continuous Terlipressin versus Vasopressin Infusion in Septic Shock (TERLIVAP): A Randomized, Controlled Pilot Study. Critical Care, 13, Article No. R130. [Google Scholar] [CrossRef] [PubMed]
[65] Vincent, J. and De Backer, D. (2013) Circulatory Shock. New England Journal of Medicine, 369, 1726-1734. [Google Scholar] [CrossRef] [PubMed]
[66] Laporte, R., Kohan, A., Heitzmann, J., Wiśniewska, H., Toy, J., La, E., et al. (2011) Pharmacological Characterization of FE 202158, a Novel, Potent, Selective, and Short-Acting Peptidic Vasopressin V1a Receptor Full Agonist for the Treatment of Vasodilatory Hypotension. The Journal of Pharmacology and Experimental Therapeutics, 337, 786-796. [Google Scholar] [CrossRef] [PubMed]
[67] Wiśniewski, K., Galyean, R., Tariga, H., Alagarsamy, S., Croston, G., Heitzmann, J., et al. (2011) New, Potent, Selective, and Short-Acting Peptidic V1a Receptor Agonists. Journal of Medicinal Chemistry, 54, 4388-4398. [Google Scholar] [CrossRef] [PubMed]
[68] O’Callaghan, D.J.P. and Gordon, A.C. (2015) What’s New in Vasopressin? Intensive Care Medicine, 41, 2177-2179. [Google Scholar] [CrossRef] [PubMed]
[69] Rehberg, S., Enkhbaatar, P., Rehberg, J., La, E., Ferdyan, N., Qi, S., et al. (2012) Unlike Arginine Vasopressin, the Selective V1a Receptor Agonist FE 202158 Does Not Cause Procoagulant Effects by Releasing Von Willebrand Factor. Critical Care Medicine, 40, 1957-1960. [Google Scholar] [CrossRef] [PubMed]
[70] Maybauer, M.O., Maybauer, D.M., Enkhbaatar, P., Laporte, R., Wiśniewska, H., Traber, L.D., et al. (2014) The Selective Vasopressin Type 1a Receptor Agonist Selepressin (FE 202158) Blocks Vascular Leak in Ovine Severe Sepsis. Critical Care Medicine, 42, e525-e533. [Google Scholar] [CrossRef] [PubMed]
[71] He, X., Su, F., Taccone, F.S., Laporte, R., Kjølbye, A.L., Zhang, J., et al. (2016) A Selective V1A Receptor Agonist, Selepressin, Is Superior to Arginine Vasopressin and to Norepinephrine in Ovine Septic Shock. Critical Care Medicine, 44, 23-31. [Google Scholar] [CrossRef] [PubMed]
[72] Vincent, J., Sakr, Y., Sprung, C.L., Ranieri, V.M., Reinhart, K., Gerlach, H., et al. (2006) Sepsis in European Intensive Care Units: Results of the SOAP Study. Critical Care Medicine, 34, 344-353. [Google Scholar] [CrossRef] [PubMed]
[73] Boyd, J.H., Forbes, J., Nakada, T., Walley, K.R. and Russell, J.A. (2011) Fluid Resuscitation in Septic Shock: A Positive Fluid Balance and Elevated Central Venous Pressure Are Associated with Increased Mortality. Critical Care Medicine, 39, 259-265. [Google Scholar] [CrossRef] [PubMed]
[74] Boucheix, O., Blakytny, R., Haroutunian, G., Henriksson, M., Laporte, R., Milano, S., et al. (2016) Selepressin and Arginine Vasopressin Do Not Display Cardiovascular Risk in Atherosclerotic Rabbit. PLOS ONE, 11, e0165422. [Google Scholar] [CrossRef] [PubMed]
[75] (2012) Abstracts of the 42nd Critical Care Congress. January 19-23, 2013. San Juan, Puerto Rico. Critical Care Medicine, 40, 1-328.
[76] Marini, J.J., Vincent, J. and Annane, D. (2015) Critical Care Evidence—New Directions. JAMA, 313, 893-894. [Google Scholar] [CrossRef] [PubMed]

为你推荐